NuCana Plc, a clinical stage biopharmaceutical company, develops cancer treatments using its ProTide technology, with key drugs NUC-3373 and NUC-7738 in various stages of clinical trials. NUC-3373 targets advanced colorectal cancer, while NUC-7738, derived from 3’-deoxyadenosine, is tested on advanced solid tumors.
NuCana plc (NCNA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, NuCana plc's actual EPS was -$3.25, missing the estimate of -$2.82 per share, resulting in a -15.09% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
